Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP11 | Q9NR21 | 12/20 | 0.56 |
| ▸ | PARP10 | Q53GL7 | 11/20 | 0.56 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.53 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4415080 | 0.84 | MAOB (0.64) | PARP11PARP10GABRG2GABRB3GABRA5 | |
| SCHEMBL22105152 | 0.78 | GABRG2 (0.53) | PARP11PARP10GABRG2GABRB3GABRA5 | |
| SCHEMBL5848736 | 0.77 | MAOA (0.68) | PARP11MAOAMAOB | |
| SCHEMBL7121540 | 0.75 | CD274 (0.46) | CD274MAOAMAOB | |
| SCHEMBL4418614 | 0.74 | MAOB (0.65) | PARP11PARP10GABRG2GABRB3GABRA5 | |
| SCHEMBL4425403 | 0.74 | MAOB (0.67) | PARP11PARP10GABRG2GABRB3GABRA5 | |
| SCHEMBL31444064 | 0.74 | MAOA (0.64) | PARP11PARP10PDPK1PARP1MAOA | |
| SCHEMBL7121552 | 0.73 | CD274 (0.47) | CD274MAOAMAOB | |
| SCHEMBL8155722 | 0.73 | PARP11 (1.00) | PARP11PARP10PDPK1PARP1GRM5 | |
| SCHEMBL21040262 | 0.73 | PARP11 (0.55) | PARP11PARP10GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6664250-B2 | Cardiovascular disorders | BRISTOL-MYERS SQUIBB CO. | 2003-12-16 | — | — | US | disclosed |
| US-20030114438-A1 | Lactam derivatives as antiarrhythmic agents | S ATWAL KARNAIL (US) | 2003-06-19 | — | — | US | disclosed |
| US-6262068-B1 | ISOQUINOLONES | BRISTOL-MYERS SQUIBB COMPANY | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114438-A1 | Lactam derivatives as antiarrhythmic agents | NPR3, SCN3A, NRDC | PARP11 4235/4885PARP10 3637/4885CD274 3287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.